Cubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
[Business Wire] – Cubist Pharmaceuticals, Inc. today announced the first detailed results from positive pivotal Phase 3 clinical trials of its antibiotic candidate ceftolozane/tazobactam in development to treat serious infections including complicated ur more
View todays social media effects on CBST
View the latest stocks trending across Twitter. Click to view dashboard